Table 1. Patient summary.
| Patient number | Gender | Age at diagnosis (years) | TNM stage | Treatment history | Osimertinib treatment line | PFS with osimertinib (months) | OS (months) | |
|---|---|---|---|---|---|---|---|---|
| All treatments received | Chemotherapy | |||||||
| P1 | Female | 58 | T2NxM1 | Gefitinib (1L); pemetrexed + bevacizumab + pallative radiotherapy (DT=30 Gy/3F) (2L); pemetrexed + nedaplatin (3L) | Yes | 4L | 11.90 | 17.33 |
| P2 | Male | 70 | TxNxM1 | Pemetrexed + cisplatin (1L); gefitinib (2L) | Yes | 3L | 13.40 | 30.41 |
| P3 | Female | 65 | T2N3M1 | Gefitinib (1L); Gemcitabine + cisplatin (2L) | Yes | 3L | 15.93 | 22.09 |
| P4 | Female | 40 | TxNxM1 | Icotinib (1L) | No | 2L | 2.07 | 2.50 |
| P5 | Female | 58 | TxNxM1 | Pemetrexed + nedaplatin (1L); icotinib (2L); gemcitabine (3L); docetaxel (4L); pemetrexed (5L) | Yes | 6L | 12.13 | 28.44 |
| P6 | Female | 40 | T4NxM1 | Gemcitabine + carboplatin (1L); gefitinib (2L); pemetrexed (3L); docetaxel (4L); afatinib + concurrent palliative T3, T4 radiotherapy (DT=3,000 cGy/10F) (5L) | Yes | 6L | 23.80 | 41.23 |
| P7 | Female | 59 | T4N2M1 | Gemcitabine+ cisplatin (1L); pemetrexed + cisplatin (2L); pemetrexed + nedaplatin (3L); gefitinib + concurrent palliative radiotherapy lower left lobe of the lung (DT=54 Gy/18F) (4L) | Yes | 5L | 21.77 | 21.93 |
| P8 | Female | 57 | TxNxM1 | Gemcitabine + nedaplatin (1L); erlotinib (2L) + concurrent palliative gamma knife chest radiotherapy (DT=3,200 Gy/4F) (2L) |
Yes | 3L | 6.53 | 9.57 |
Prior EGFR-TKI therapies received by the patient were underlined. T, tumor; N, node; M, metastasis; xL, denotes line of treatment (i.e., 1L, first-line); DT, radiation dose; Gy, gray; F, fraction; PFS, progression-free survival; OS, overall survival.